Patent ID: 8324266

Claim:
A method for treating a pulmonary disease or disorder in a patient, the method comprising: providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension, the co-suspension comprising: a suspension medium comprising a pharmaceutically acceptable propellant free of additional constituents; a first species of respirable active agent particles comprising a pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate in crystalline form, as a first active agent; one or more additional species of respirable active agent particles comprising one or more additional active agents selected from the group consisting of a short-acting beta agonist, a long-acting and ultra long-acting β 2 adrenergic receptor agonist (LABA), a corticosteroid, an anti-inflammatory, an anti-tussive, a bronchodilator, and a muscarinic antagonist; and a plurality of respirable suspending particles, wherein the total mass of the respirable suspending particles exceeds the total mass of the respirable active agent particles, the plurality of suspending particles are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium, and the active agent particles associate with the plurality of suspending particles to form a co-suspension; and administering the co-suspension to the patient by actuating the metered dose inhaler, wherein said administering of the co-suspension comprises delivering a dose of 150 μg or less of glycopyrrolate per actuation of the metered dose inhaler and said delivery results in an increase in FEV 1 of at least 70 mL in 0.5 hours or less, and the at least 70 mL increase in FEV 1 remains for up to 12 hours or more.